14 results on '"Funahashi, Kimihiko"'
Search Results
2. Peritoneal lavage cytology in patients with curative resection for stage II and III colorectal cancer: A multi‐institutional prospective study.
- Author
-
Kobayashi, Hirotoshi, Kotake, Kenjiro, Maeda, Kotaro, Suto, Takeshi, Kawasaki, Masayasu, Ueno, Hideki, Komori, Koji, Ozawa, Heita, Koda, Keiji, Ohue, Masayuki, Funahashi, Kimihiko, Takemasa, Ichiro, Ishida, Hideyuki, Kazama, Shinsuke, Shimada, Yoshifumi, Morohashi, Hajime, Kinugasa, Yusuke, Kanemitsu, Yukihide, Ochiai, Hiroki, and Ishihara, Soichiro
- Subjects
PERITONEAL dialysis ,COLORECTAL cancer ,CYTOLOGY ,LONGITUDINAL method ,OVERALL survival ,BRONCHOALVEOLAR lavage - Abstract
Aim: To clarify the usefulness of intraoperative lavage cytology in patients undergoing curative resection for pStage II‐III colorectal cancer in a prospective multicenter study. Methods: Patients preoperatively diagnosed with stage II‐III colorectal cancer between 2013 and 2017 from 20 hospitals were enrolled. Lavage cytology was performed twice during the surgery. The primary endpoint was the effect of lavage cytology on the 5‐year relapse‐free survival (RFS) in patients with pStage II‐III colorectal cancer. The secondary endpoint was the effect of lavage cytology on the 5‐year overall survival (OS) and peritoneal recurrence. Results: A total of 1378 patients were eligible for analysis. The number of patients with pStage II‐III colorectal cancer was 670 and 708, respectively. Fifty‐four patients (3.9%) had positive cytological results. In pStage II patients, the 5‐year RFS rates with positive and negative cytology were 61.1% and 81.6%, respectively (p = 0.023). The 5‐year OS rates were 67.1% and 91.7%, respectively (p = 0.0083). However, there was no difference in RFS or OS between pStage III patients with positive and negative cytology results. The peritoneal recurrence rates were 11.8% and 1.5% in pStage II patients with positive and negative cytology results, respectively (p = 0.032). These rates were 10.5% and 2.5% in patients with stage III disease, respectively (p = 0.022). Conclusion: Stage II colorectal cancer patients with negative cytology had better outcomes than those with positive cytology. Peritoneal lavage cytology is useful for predicting peritoneal recurrence after curative resection of stage II‐III colorectal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA
- Author
-
Ushigome, Mitsunori, Shimada, Hideaki, Miura, Yasuyuki, Yoshida, Kimihiko, Kaneko, Tomonori, Koda, Takamaru, Nagashima, Yasuo, Suzuki, Takayuki, Kagami, Satoru, and Funahashi, Kimihiko
- Published
- 2020
- Full Text
- View/download PDF
4. Factors affecting R0 resection of colorectal cancer with synchronous peritoneal metastases: a multicenter prospective observational study by the Japanese Society for Cancer of the Colon and Rectum
- Author
-
Shida, Dai, Kobayashi, Hirotoshi, Kameyama, Masao, Hase, Kazuo, Maeda, Kotaro, Suto, Takeshi, Itabashi, Michio, Funahashi, Kimihiko, Koyama, Fumikazu, Ozawa, Heita, Noura, Shingo, Ishida, Hideyuki, Kanemitsu, Yukihide, Kotake, Kenjiro, and Sugihara, Kenichi
- Published
- 2020
- Full Text
- View/download PDF
5. Multi-panel assay of serum autoantibodies in colorectal cancer
- Author
-
Ushigome, Mitsunori, Nabeya, Yoshihiro, Soda, Hiroaki, Takiguchi, Nobuhiro, Kuwajima, Akiko, Tagawa, Masatoshi, Matsushita, Kazuyuki, Koike, Junichi, Funahashi, Kimihiko, and Shimada, Hideaki
- Published
- 2018
- Full Text
- View/download PDF
6. A proposed new Japanese classification of synchronous peritoneal metastases from colorectal cancer: A multi‐institutional, prospective, observational study conducted by the Japanese Society for Cancer of the Colon and Rectum.
- Author
-
Kobayashi, Hirotoshi, Kotake, Kenjiro, Kawasaki, Masayasu, Kanemitsu, Yukihide, Kinugasa, Yusuke, Ueno, Hideki, Maeda, Kotaro, Suto, Takeshi, Itabashi, Michio, Funahashi, Kimihiko, Ozawa, Heita, Koyama, Fumikazu, Noura, Shingo, Ishida, Hideyuki, Ohue, Masayuki, Kiyomatsu, Tomomichi, Ishihara, Soichiro, Koda, Keiji, Baba, Hideo, and Kawada, Kenji
- Abstract
Aim: To establish a new Japanese classification of synchronous peritoneal metastases from colorectal cancer. Methods: This multi‐institutional, prospective, observational study enrolled patients who underwent surgery for colorectal cancer with synchronous peritoneal metastases. Overall survival rates were compared according to the various models using objective indicators. Each model was evaluated by Akaike's information criterion (AIC). The region of peritoneal metastases was evaluated by the peritoneal cancer index (PCI). Results: Between October 2012 and December 2016, 150 patients were enrolled. The AIC of the present Japanese classification was 1020.7. P1 metastasis was defined as confined to two regions. The minimum AIC was obtained with the cutoff number of 10 or less for P2 metastasis and 11 or more for P3 metastasis. As for size, the best discrimination ability between P2 and P3 metastasis was obtained with a cutoff value of 3 cm. The AIC of the proposed classification was 1014.7. The classification was as follows: P0, no peritoneal metastases; P1, metastases localized to adjacent peritoneum (within two regions of PCI); P2, metastases to distant peritoneum, number ≤10 and size ≤3 cm; P3, metastases to distant peritoneum, number ≥11 or size >3 cm; P3a, metastases to distant peritoneum, number ≥11 and size ≤3 cm, or number ≤10 and size >3 cm; P3b, metastases to distant peritoneum, number ≥11 and size >3 cm. Conclusion: This objective classification could improve the ability to discriminate prognosis in patients with synchronous peritoneal metastases from colorectal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Estrogen receptor beta expression in colitis‐associated carcinoma in comparison with sporadic colonic tumor: An immunohistochemical study.
- Author
-
Matsuno, Takahisa, Mikami, Tetuo, Hayashi, Hiroyuki, Funahashi, Kimihiko, Okazumi, Shinichi, Hiruta, Nobuyuki, Shibuya, Kazutoshi, and Igarashi, Yoshinori
- Subjects
COLON tumors ,ESTROGEN receptors ,CARCINOMA ,ULCERATIVE colitis ,COLORECTAL cancer ,ADENOMATOUS polyps - Abstract
Background and Aim: The rate of ulcerative colitis (UC)‐related colorectal cancer (colitis‐associated carcinoma) is increasing. Estrogen receptor (ER) beta expression has been studied separately in patients with sporadic colorectal cancer and those with colitis‐associated carcinoma. However, no study has compared the expression in both of these cancer types. The present study aimed to evaluate the relationship between colitis‐associated carcinoma and ERs and assess whether the expression of ER beta influences cell proliferation. Methods: This study included 45 surgically operated colitis‐associated carcinomas, 43 high‐grade dysplasias, 34 low‐grade dysplasias, 36 sporadic colorectal cancers, 44 high‐grade adenomas, and 34 low‐grade adenomas. ER beta expression was evaluated with immunohistochemistry. Results: Colitis‐associated carcinoma showed significantly lower ER beta immunoexpression than sporadic colorectal lesions and high‐ and low‐grade dysplasia. In seven colitis‐associated carcinoma harboring both intensity score 3 (strong immunoexpression) and score 1 (weak immunoexpression) areas, the correlation among ER beta intensity, Ki‐67, and p21 labeling index was assessed; an area with an ER beta intensity score of 3 showed a higher Ki‐67 labeling index than that with score 1. In four out of the seven lesions, p21 labeling index was higher in the area of ER beta score 1 than in that of ER beta score 3. Conclusions: The data suggest that ER beta expression is an accelerating factor in colorectal tumors. This association may be lower in colitis‐associated carcinoma than in sporadic colorectal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis
- Author
-
Kobayashi, Hirotoshi, Kotake, Kenjiro, Funahashi, Kimihiko, Hase, Kazuo, Hirata, Koichi, Iiai, Tsuneo, Kameoka, Shingo, Kanemitsu, Yukihide, Maeda, Koutarou, Murata, Akihiko, Ohue, Masayuki, Shirouzu, Kazuo, Takahashi, Keiichi, Watanabe, Toshiaki, Yano, Hideaki, Yatsuoka, Toshimasa, Hashiguchi, Yojiro, Sugihara, Kenichi, and Study Group for Peritoneal Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum
- Published
- 2014
- Full Text
- View/download PDF
9. The metabolic parameters based on volume in PET/CT are associated with clinicopathological N stage of colorectal cancer and can predict prognosis.
- Author
-
Kido, Hidenori, Kato, Shunsuke, Funahashi, Kimihiko, Shibuya, Kazutoshi, Sasaki, Yousuke, Urita, Yoshihisa, Hori, Masaaki, and Mizumura, Sunao
- Subjects
COLORECTAL cancer ,POSITRON emission tomography computed tomography ,PROGNOSIS ,BREAST cancer prognosis ,COMPUTED tomography ,LEAN body mass ,CANCER prognosis ,TUMOR classification - Abstract
Background: A combination of positron emission tomography and computed tomography (PET/CT) is an important modality for the diagnosis of carcinoma. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have been reported as metabolic parameters in PET/CT since the late 1990s, and they are expected to be useful in diagnosing diverse cancers and as prognostic biomarkers. We evaluated the potential of these parameters in the prognosis of colorectal cancer (CRC) by comparing them with conventional parameters, including the maximum standardized uptake value (SUVmax). We enrolled 84 patients who underwent surgery for CRC without distal metastasis between April 2015 and April 2019. SUVmax, MTV, and TLG were measured by
18 F-fluorodeoxyglucose (FDG)-PET/CT. To find an optimal threshold value related to prognosis, the volume of interest in the primary carcinoma was measured at fixed relative and absolute thresholds based on SUVmax (30%, 40%, and 50%; 2.5, 3.0, and 3.5, respectively), tumor-to-liver standardized uptake ratios, TLR (1.0, 1.5, and 2.0), and SUV normalized to lean body mass, SUL (2.0, 2.5, and 3.0). After classifying the patients into two groups according to pathological N stage, the optimal threshold values of all metabolic parameters were compared between groups using a non-parametric comparison test. Result: The most suitable thresholds for MTV were a SUVmax of 3.5 and a TLR 2.0. TLG with a SUVmax value of 40% showed the most significant difference. The MTV standard uptake ratio of 2.0 was significantly associated with pathological N stage. Conclusion: Our results suggest that an MTV TLR 2.0 on PET/CT reflects pathological N stage in local patients with CRC. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
10. Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.
- Author
-
Ito, Masaaki, Hiwasa, Takaki, Oshima, Yoko, Yajima, Satoshi, Suzuki, Takashi, Nanami, Tatsuki, Sumazaki, Makoto, Shiratori, Fumiaki, Funahashi, Kimihiko, Li, Shu-Yang, Iwadate, Yasuo, Yamagata, Hiroki, Jambaljav, Byambasteren, Takemoto, Minoru, Yokote, Koutaro, Takizawa, Hirotaka, and Shimada, Hideaki
- Subjects
ESOPHAGEAL cancer ,WESTERN immunoblotting ,PROGNOSIS ,ONCOLOGIC surgery ,OVERALL survival ,CANCER prognosis ,COLORECTAL cancer - Abstract
Background: Esophageal cancer often appears as postoperative metastasis or recurrence after radical surgery. Although we had previously reported that serum programmed cell death ligand 1 (PD-L1) level correlated with the prognosis of esophageal cancer, further novel biomarkers are required for more precise prediction of the prognosis. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with the cholesterol metabolism. But there was no report of relationship between serum PCSK9 antibody and cancer. Therefore, we investigated whether anti-PCSK9 antibodies could be a novel biomarker for solid cancer. Methods: Serum levels of anti-PCSK9 antibodies and antigens in patients with solid cancer were analyzed using amplified luminescence proximity homogeneous assay-linked immunosorbent assay (AlphaLISA). The reactivity of serum antibodies against recombinant PCSK9 protein was investigated by Western blotting, and the expression of PCSK9 antigens in esophageal cancer tissues was examined by immunohistochemical staining. Results: AlphaLISA showed that serum anti-PCSK9 antibody (s-PCSK9-Ab) levels were significantly higher in patients with esophageal cancer, gastric cancer, colorectal cancer, lung cancer, and breast cancer than in healthy donors, and patients with esophageal cancer had the highest levels. The presence of serum antibody in patients was confirmed by Western blotting. There was no apparent correlation between s-PCSK9-Ab and PCSK9 antigen levels. Immunohistochemical staining demonstrated the expression of PCSK9 antigen in both the cytoplasm and nuclear compartments of esophageal squamous cell carcinoma tissue but not in normal tissue. Compared with patients with low s-PCSK9-Ab levels, those with high s-PCSK9-Ab levels had a favorable postoperative prognosis after radical surgery for esophageal cancer. In the multivariate analysis, tumor depth and s-PCSK9-Ab level were identified as independent prognostic factors. In the univariate analysis of clinicopathological features, high PCSK9 antibody levels were not associated with sex, age, location, tumor depth, lymph node status, squamous cell carcinoma antigen, or p53-Ab, whereas they correlated significantly with PD-L1 levels, which were associated with unfavorable prognosis. Correlation between s-PCSK9-Ab and PD-L1 levels was also confirmed in the logistic regression analysis; therefore, low s-PCSK9-Ab levels could discriminate another poor prognosis group other than high-PD-L1 group. Conclusions: Patients with solid cancer had higher s-PCSK9-Ab levels than healthy donors. High s-PCSK9-Ab levels indicated better prognosis for overall survival after surgery in patients with esophageal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Prognostic and diagnostic significance of preoperative Jumonji domain‑containing 6 antibodies in colorectal cancer.
- Author
-
Yoshida, Kimihiko, Hiwasa, Takaki, Ito, Masaaki, Ushigome, Mitsunori, Takizawa, Hirotaka, Li, Shu-Yang, Zhang, Bo-Shi, Iwadate, Yasuo, Funahashi, Kimihiko, and Shimada, Hideaki
- Subjects
COLORECTAL cancer ,CARCINOEMBRYONIC antigen ,RECEIVER operating characteristic curves ,IMMUNOGLOBULINS - Abstract
Jumonji domain-containing 6 (JMJD6) protein has been reported to be upregulated in different cancer cells; however, to the best of our knowledge, no report has analyzed serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with cancer. Therefore, the present study evaluated the clinical significance of s-JMJD6-Abs in patients with colorectal cancer. Preoperative serum samples were analyzed from 167 patients with colorectal cancer who underwent radical surgery between April 2007 and May 2012. The pathological stages were as follows Stage I (n=47), stage II (n=56), stage III (n=49) and stage IV (n=15). In addition, 96 healthy participants were analyzed as controls. s-JMJD6-Abs were analyzed by amplified luminescent proximity homology assay-linked immunosorbent assay. The cutoff value of s-JMJD6-Abs for detecting colorectal cancer was calculated to be 5,720 using the receiver operating characteristic curve. The positive rate of s-JMJD6-Abs was 37% in patients with colorectal cancer (61 of 167), independent of carcinoembryonic antigen or carbohydrate antigen 19-9 and p53-Abs. Clinicopathological factors and prognosis were compared between the s-JMJD6-Abs-positive group and the s-JMJD6-Abs-negative group. The s-JMJD6-Ab-positive status was significantly associated with older age (P=0.03), but was not associated with other clinicopathological variables. Regarding recurrence-free survival, the s-JMJD6-positive status was a significant poor prognostic factor in both univariate (P=0.02) and multivariate (P<0.01) analyses. Similarly, regarding overall survival, the s-JMJD6-Abs-positive status was a significant poor prognostic factor in both univariate (P=0.03) and multivariate (P=0.01) analyses. In conclusion, preoperative s-JMJD6-Abs was positive in 37% of patients with colorectal cancer and may be considered an independent poor prognostic biomarker. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Identification of serum anti-striatin 4 antibodies as a common marker for esophageal cancer and other solid cancers.
- Author
-
Ito, Masaaki, Hiwasa, Takaki, Oshima, Yoko, Yajima, Satoshi, Suzuki, Takashi, Nanami, Tatsuki, Sumazaki, Makoto, Shiratori, Fumiaki, Funahashi, Kimihiko, Takizawa, Hirotaka, Kashiwado, Koichi, Tochigi, Naobumi, and Shimada, Hideaki
- Subjects
ESOPHAGEAL cancer ,TUMOR markers ,CANCER prognosis ,IMMUNOGLOBULINS ,COLORECTAL cancer ,ONCOLOGIC surgery ,LUMINESCENCE - Abstract
Solid cancers have a poor prognosis, and their morbidity and mortality after surgery is high. Even after radical surgery for esophageal cancer, there have been cases of early postoperative death. The present study therefore aimed to explore new tumor markers that can predict the early postoperative prognosis. To identify antibody markers, serological antigens were identified using recombinant cDNA expression cloning (SEREX). The results identified striatin 4 (STRN4) as the antigen recognized by serum IgG antibodies in patients with esophageal cancer. After performing an amplified luminescence proximity homogeneous assay-linked immunosorbent assay (AlphaLISA), it was revealed that when compared with healthy donors, serum anti-STRN4 antibody (STRN4-Ab) levels were significantly higher not only in patients with esophageal cancer but also to lesser extent, in those with gastric cancer, colorectal cancer, lung cancer and breast cancer. Compared with STRN4-Ab-negative patients with esophageal cancer, STRN4-Ab-positive patients had a poorer postoperative prognosis at early stages, suggesting that STRN4-Abs may be useful for predicting poor early-stage prognoses of patients with esophageal cancer. The positive diagnosis rates of esophageal cancer using the STRN4-Ab marker and conventional markers, including squamous cell carcinoma antigen and p53 antibody alone, were 26.4, 35.2 and 19.1% respectively; a result that increased up to 59.1% by combining all three markers. Serum STRN4-Ab may serve as a novel marker of esophageal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Possible predictive significance of serum RalA autoantibodies on relapse-free survival in patients with colorectal cancer.
- Author
-
Ushigome, Mitsunori, Shimada, Hideaki, Nabeya, Yoshihiro, Shiratori, Fumiaki, Soda, Hiroaki, Takiguchi, Nobuhiro, Hoshino, Isamu, Kuwajima, Akiko, Kaneko, Tomoaki, and Funahashi, Kimihiko
- Subjects
COLORECTAL cancer ,TUMOR antigens ,AUTOANTIBODIES ,CANCER patients ,SURVIVAL analysis (Biometry) - Abstract
RalA protein, a member of the Ras superfamily of small GTPases, is a tumor antigen that induces serum RalA antibodies (s-RalA-Abs). The present study explored the clinicopathological and prognostic significance of s-RalA-Abs in patients with colorectal cancer. Serum samples were obtained from 314 patients with colorectal cancer at stage 0/I (n=71), stage II (n=86), stage III (n=78), stage IV (n=64) and recurrence (n=15). Samples were analyzed for the presence of s-RalA-Abs using ELISA. The cutoff optical density value was fixed at 0.324 (mean of heathy controls + 3 standard deviations). The overall positive rate for serum anti-RalA antibodies was 14%. The presence of s-RalA-Abs was not significantly associated with clinicopathological characteristic factors. Additionally, the s-RalA-Abs(+) group demonstrated significantly poor relapse-free survival rates. The s-RalA-Abs (+)/carcinoembryonic antigen (CEA)(+) group exhibited the worst prognosis and s-RalA-Abs(+)/CEA(+) was an independent risk factor for poor relapse-free survival. Although the positive rate was not high, s-RalA-Abs may be a useful predictor of poor relapse-free survival in patients with colorectal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
14. Down-regulation of MutS homolog 3 by hypoxia in human colorectal cancer
- Author
-
Li, Jie, Koike, Junichi, Kugoh, Hiroyuki, Arita, Michitsune, Ohhira, Takahito, Kikuchi, Yoshinori, Funahashi, Kimihiko, Takamatsu, Ken, Boland, C. Richard, Koi, Minoru, and Hemmi, Hiromichi
- Subjects
- *
COLON cancer , *GENETIC regulation , *HOMOLOGY (Biology) , *HYPOXEMIA , *GLUCOSE transporters , *BIOMARKERS , *GENE expression , *CANCER cells , *MICROSATELLITE repeats - Abstract
Abstract: Down-regulation of hMSH3 is associated with elevated microsatellite alterations at selected tetranucleotide repeats and low levels of microsatellite instability in colorectal cancer (CRC). However, the mechanism that down-regulates hMSH3 in CRC is not known. In this study, a significant association between over-expression of glucose transporter 1, a marker for hypoxia, and down-regulation of hMSH3 in CRC tissues was observed. Therefore, we examined the effect of hypoxia on the expression of hMSH3 in human cell lines. When cells with wild type p53 (wt-p53) were exposed to hypoxia, rapid down-regulation of both hMSH2 and hMSH3 occurred. In contrast, when null or mutated p53 (null/mut-p53) cells were exposed to hypoxia, only hMSH3 was down-regulated, and at slower rate than wt-p53 cells. Using a reporter assay, we found that disruption of the two putative hypoxia response elements (HREs) located within the promoter region of the hMSH3 abrogated the suppressive effect of hypoxia on reporter activity regardless of p53 status. In an EMSA, two different forms of HIF-1α complexes that specifically bind to these HREs were detected. A larger complex containing HIF-1α predominantly bound to the HREs in hypoxic null/mut-p53 cells whereas a smaller complex predominated in wt-p53 cells. Finally, HIF-1α knockdown by siRNA significantly inhibited down-regulation of hMSH3 by hypoxia in both wt-p53 and mut-p53 cells. Taken together, our results suggest that the binding of HIF-1α complexes to HRE sites is necessary for down-regulation of hMSH3 in both wt-p53 and mut-p53 cells. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.